Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years.

被引：0
|
作者：
Genovese, Mark C. [1 ]
Sebba, Anthony [2 ]
Rubbert-Roth, Andrea [3 ]
Jose Scali, Juan [4 ]
Alten, Rieke [5 ]
Kremer, Joel M. [6 ]
Pitts, Laura [7 ]
Vernon, Emma [7 ]
van Vollenhoven, Ronald F. [8 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Univ S Florida, Tampa, FL USA
[3] Univ Cologne, D-50931 Cologne, Germany
[4] Durand Univ Hosp, Buenos Aires, DF, Argentina
[5] Univ Med Berlin, Schlosspk Klin, Berlin, Germany
[6] Albany Med Coll, Albany, NY 12208 USA
[7] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[8] Karolinska Inst, Stockholm, Sweden
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1640
引用
收藏
页码：S700 / S701
页数：2
相关论文
共 50 条
  • [1] LONG-TERM SAFETY OF TOCILIZUMAB (TCZ) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND A MEAN TREATMENT DURATION OF 3.7 YEARS
    Smith, M.
    Taylor, A.
    Youssef, P.
    Hall, S.
    Nash, P.
    Sebba, A.
    Rubbert-Roth, A.
    Scali, J.
    Alten, R.
    Kremer, J.
    Pitts, L.
    Van Vollenhoven, R.
    Genovese, M.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 : 33 - 33
  • [2] Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis following a Mean Treatment Duration of 3.9 Years
    Haraoui, Boulos
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Scali, Juan
    Alten, Rieke
    Kremer, Joel
    Pitts, Laura
    Vernon, Emma
    van Vollenhoven, Ronald
    Genovese, Mark
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1508 - 1508
  • [3] LONG-TERM SAFETY OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING A MEAN TREATMENT DURATION OF 3.9 YEARS
    Genovese, M.
    Sebba, A.
    Rubbert-Roth, A.
    Scali, J.
    Alten, R.
    Kremer, J.
    Pitts, L.
    Vernon, E.
    van Vollenhoven, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 461 - 461
  • [4] LONG-TERM SAFETY OF TOCILIZUMAB IN RA PATIENTS TREATED FOR A MEAN DURATION OF 3.7 YEARS
    Genovese, Mark
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Scali, Juan J.
    Alten, Rieke
    Kremer, Joel M.
    Pitts, Laura
    Vernon, Emma
    van Vollenhoven, Ronald F.
    [J]. RHEUMATOLOGY, 2013, 52 : 93 - 94
  • [5] LONG-TERM SAFETY OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING A MEAN TREATMENT DURATION OF 3.9 YEARS (ENCORE)
    Genovese, M.
    Sebba, A.
    Youssef, P.
    Rischmueller, M.
    Jones, G.
    Rubbert-Roth, A.
    Scali, J.
    Alten, R.
    Kremer, J.
    Pitts, L.
    Rowell, L.
    Van Vollenhoven, R.
    [J]. INTERNAL MEDICINE JOURNAL, 2014, 44 : 25 - 25
  • [6] Safety of Tocilizumab in Patients with Rheumatoid Arthritis: An Interim Analysis of Long-Term Extension Trials with a Mean Treatment Duration of 1.5 Years
    Haraoui, Boulos
    van Vollenhoven, Ronald F.
    Smolen, Josef S.
    [J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2596 - 2596
  • [7] Safety of tocilizumab in patients with rheumatoid arthritis: An interim analysis of long-term extension trials with a mean treatment duration of 1.5 years
    van Vollenhoven, Ronald F.
    Smolen, Josef
    Tony, Hans P. T.
    Codding, Christine
    Keystone, Ed C.
    Woodworth, Thasia
    Alecock, Emma
    Alten, Ricke
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S784 - S785
  • [8] Long-Term Safety and Tolerability of Tocilizumab in Patients with a Mean Treatment Duration of 2.4 Years
    Van Vollenhoven, Ronald
    McCarthy, Tim
    Siri, Daniel
    [J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1299 - 1299
  • [9] Tocilizumab (TCZ) Long-Term Efficacy in Rheumatoid Arthritis (RA) Patients (pts) Treated up to 3.7 Years
    Khraishi, Majed
    Haraoui, Boulos
    Alten, Rieke
    Gomez-Reino, Juan
    Rizzo, Warren
    Schechtman, Joy
    Kahan, Andre
    Vernon, Emma
    Taylor, Monet
    Smolen, Joseph
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1164 - 1164
  • [10] LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS)
    van Vollenhoven, Ronald
    Scali, Juan
    Curtis, Jeffrey R.
    Krasnow, Joel
    Vernon, Emma
    Alten, Rieke
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1087 - 1087
12345